Last $5.93 USD
Change Today +0.11 / 1.89%
Volume 12.0K
CORI On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 4:00 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Open
$5.85
Previous Close
$5.82
Day High
$5.96
Day Low
$5.85
52 Week High
06/18/14 - $8.49
52 Week Low
08/12/14 - $5.61
Market Cap
106.7M
Average Volume 10 Days
19.4K
EPS TTM
--
Shares Outstanding
18.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORIUM INTERNATIONAL INC (CORI)

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the research, development, manufacture, and commercialization of specialty pharmaceutical products. Its products include Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for management of chronic pain, including cancer-related pain; Crest Whitestrips, a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company is also developing AG200-15, a combination hormonal contraceptive patch in Phase III clinical trials that delivers ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system, which has completed Phase I clinical trials for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed Phase I clinical trials for the treatment of benign prostatic hyperplasia. In addition, its products that have completed development, scale-up, and clinical activities include motion sickness patch for the prevention of nausea and vomiting associated with motion sickness; and urology patch for treatment of a urologic condition. Further, the company is developing Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company, Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Inc., and Agile Therapeutics, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

245 Employees
Last Reported Date: 04/3/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $418.6K
Executive Chairman and Chairman of Audit Comm...
Total Annual Compensation: $62.4K
Co-Founder and Director
Total Annual Compensation: $35.3K
Chief Financial Officer
Total Annual Compensation: $342.9K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $282.1K
Compensation as of Fiscal Year 2013.

corium international inc (CORI) Key Developments

Corium International, Inc. Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014

Corium International, Inc. announced consolidated unaudited earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported total revenues of $10,183,000 against $12,566,000 a year ago. The reduction in total revenues in the third fiscal quarter of 2014 primarily reflects the anticipated declines in full-year product revenues from both Clonidine TDS (marketed by Teva Pharmaceuticals) and Fentanyl TDS (marketed by Par Pharmaceutical), as well as reductions in contract research and development revenues from programs that have reached the final stages of process development, partially offset by an increase in sales of Crest Whitestrips to P&G and an increase in contract research and development revenues from new co-development programs as well as partner-funded programs. Without the effect of charge, Corium would have recognized a non-GAAP net loss for the third fiscal quarter of 2013 of $1.2 million. Loss from operations was $3,397,000 against income from operations of $771,000 a year ago. Loss before income taxes was $4,981,000 against $9,163,000 a year ago. Net loss and comprehensive loss was $4,981,000 against $9,163,000 a year ago. Net loss per basic and diluted share attributable to common stockholders was $0.28 against $4.12 a year ago. For the nine months, the company reported total revenues of $31,368,000 against $37,726,000 a year ago. Loss from operations was $5,253,000 against income from operations of $1,030,000 a year ago. Loss before income taxes was $3,545,000 against $12,595,000 a year ago. Net loss and comprehensive loss was $3,545,000 against $12,595,000 a year ago. Net loss per basic and diluted Share attributable to common stockholders was $0.48 against $5.69 a year ago.

Corium International, Inc. to Report Q3, 2014 Results on Aug 12, 2014

Corium International, Inc. announced that they will report Q3, 2014 results After-Market on Aug 12, 2014

Corium International, Inc., Q3 2014 Earnings Call, Aug 12, 2014

Corium International, Inc., Q3 2014 Earnings Call, Aug 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $5.93 USD +0.11

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.50 USD -0.10
Actavis plc $226.25 USD +2.89
CVS Caremark Corp $78.98 USD -0.63
Mylan Inc/PA $47.75 USD -0.84
Walgreen Co $61.07 USD -0.93
View Industry Companies
 

Industry Analysis

CORI

Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit www.coriumgroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.